Promising PTSD drug moves to Long-Term safety study
Disease control
ENROLLING_BY_INVITATION
This study is testing the long-term safety and effectiveness of a drug called TSND-201 for adults with PTSD. Participants who completed an earlier blinded trial of TSND-201 can receive up to three treatment courses over 48 weeks, each consisting of four weekly doses. The goal is …
Phase: PHASE3 • Sponsor: Transcend Therapeutics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC